Immunogenicity and safety of ZOSTAVAX®approaching expiry potency in individuals aged ≥50 years

Human Vaccines

Volumn 7, Issue 10, 2011, Pages

  Arnou, Robert ^a   Fiquet, Anne ^b   Thomas, Stéphane ^b   Sadorge, Christine ^b  

^a ALTI Clinical Research Network   (France)

^b SANOFI PASTEUR   (France)

Author keywords

Clinical study; Elderly; Expiry potency; Herpes zoster; Immunogenicity; Safety; Vaccine; ZOSTAVAX

Indexed keywords

HERPES ZOSTER IMMUNOGLOBULIN; VARICELLA ZOSTER VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; ASTHENIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FRANCE; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE SWELLING; KERATITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARESTHESIA; PHASE 4 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; PRURITUS; SINGLE DRUG DOSE; TREATMENT RESPONSE; VACCINATION; VARICELLA ZOSTER VIRUS; VESICULAR RASH; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC;

EID: 85046980777     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.10.16480     Document Type: Article

References (45)

1. th edn. Lippincott Williams & Wilkins, Philadelphia 2001; 2:2731-68.
2. Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA 1995; 92:10980-4; PMID:7479921; DOI:10.1073/pnas.92.24.10980.
3. Gauthier A, Breuer J, Carrington D, Martini M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137:38-47; PMID:18466661; DOI:10.1017/ S0950268808000678.
4. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340-6; PMID:12151472; DOI:10.1056/NEJMcp013211.
5. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481-6; PMID:11317250; DOI:10.1086/320169.
6. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008; 197:207-15; PMID:18419399; DOI:10.1086/522152.
7. Johnson RW, Wasner G, Saddier P, Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25:991-1006; PMID:19021299; DOI:10.2165/0002512-200825120-00002.
8. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; 15:6866; PMID:19370655.
9. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571-5; PMID:1195231.
10. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70:24-30; PMID:12627483; DOI:10.1002/jmv.10316.
11. Meister W, Neiss A, Gross G, Doerr HW, Höbel W, Malin JP, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998; 26:359-63; PMID:9861560; DOI:10.1007/BF02770836.
12. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45:52-3; PMID:8545021.
13. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18:350-4; PMID:12441828; DOI:10.1097/00002508-200211000-00002.
14. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344-56; PMID:15336639; DOI:10.1016/j.jpain.2004.06. 001.
15. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342-8; PMID:15307000; DOI:10.1086/421942.
16. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6:356-63; PMID:15943957; DOI:10.1016/j.jpain.2005.01.359.
17. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006; 35:132-7; PMID:16431855; DOI:10.1093/ageing/afj048.
18. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490-6; PMID:17575488; DOI:10.1097/AJP.0b013e318065b6c9.
19. Weinke T, Edite A, Schmitt S, Lukas K. Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey. J Public Health 2010; 18:367-74; PMID:21124645; DOI:10.1007/s10389-010-0323-0.
20. Aspinall R, Del Giudice G, Effros RB, Grubeck- Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007; 4:9; PMID:18072962; DOI:10.1186/1742-4933-4-9.
21. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002; 2:659-66; PMID:12409046; DOI:10.1016/S1473-3099(02)00437-1.
22. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology 2007; 120:435-46; PMID:17313487; DOI:10.1111/j.1365-2567.2007.02555.x.
23. Johnson RW. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination. Aging Clin Exp Res 2009; 21:236-43; PMID:19571648.
24. Yawn BP, Saddier P, Wollan PC, St. Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341-9; PMID:17976353; DOI:10.4065/82.11.1341.
25. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127:305-14; PMID:11693508; DOI:10.1017/ S0950268801005921.
26. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9; PMID:7618983; DOI:10.1001/archinte.155.15. 1605.
27. Dworkin RH, Gnann JW Jr, Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9:37-44; PMID:18166464; DOI:10.1016/j.jpain.2007.10.008.
28. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166:253-9; PMID:1321859; DOI:10.1093/infdis/166.2.253.
29. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:41-6; PMID:8545018.
30. Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178:109-12; PMID:9852987; DOI:10.1086/514264.
31. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336-44; PMID:14593591; DOI:10.1086/379048.
32. Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000; 18:1700-6; PMID:10689152; DOI:10.1016/S0264-410X(99)00510-1.
33. Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al. for the ZOSTAVAX Protocol 010 Study Group. A double-blind, randomized, controlled, multicenter safety and immunogenicity of a refrigerator stable formulation of Zostavax®. Clin Vaccine Immunol 2008; 15:314-9; PMID:18077611; DOI:10.1128/CVI.00310-07.
34. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; DOI:10.1056/NEJMoa051016.
35. Oxman MN, Levin MJ. Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197:228-36; PMID:18419402; DOI:10.1086/522159.
36. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010; 152:545-54; PMID:20439572.
37. ZOSTAVAX® Summary of Product Characteristics. May 2006. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/zostavax/emea-combinedh674en.pdf
38. Arvin A. Aging, immunity and the varicella-zoster virus. N Engl J Med 2005; 352:2266-7; PMID:15930416; DOI:10.1056/NEJMp058091.
39. MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin 2010; 6:894-902; PMID:20980796; DOI:10.4161/hv.6.11.12852.
40. Sanford M, Keating GM. Zoster vaccine (ZOSTAVAX®). A review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27:159-76; PMID:20104941; DOI:10.2165/10489140.
41. World Medical Association Declaration Of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Accessed on 07 Jan 2010; at: http://www.wma.net/en/30publications/10policies/b3/index.html
42. Note For Guidance On Good Clinical Practice. (CPMP/ICH/135/95), 1997. Accessed on 07 Jan 2010; at: http://www.ema.europa.eu/pdfs/human/ich/013595en. pdf
43. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (VARIVAX®) in children and adults. Vaccine 1997; 15:61-4; PMID:9041667; DOI:10.1016/S0264-410X(96)00107-7.
44. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35; PMID:18419349; DOI:10.1086/528696.
45. Fontaine N, Rosengren B. The European Parliament and the council of the European Union. Directive 2001/20/EC relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Luxembourg, 4 April 2001. Available at: http://www.eortc.be/Services/ Doc/clinical-EU-directive-04-April-01.pdf. Last accessed June 3 2011.